We are live on ! Find out more
GCTK icon

GlucoTrack

2 hedge funds and large institutions have $743K invested in GlucoTrack in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3,915% more capital invested

Capital invested by funds: $18.5K → $743K (+$724K)

0% more ownership

Funds ownership: 0%0% (+0%)

Holders
2
Holders Change
+2
Holders Change %
% of All Funds
0.03%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

GCTK Hedge Fund Activity: Q2 2023 in Review

2 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in GlucoTrack (GCTK) for Q2 2023, worth a combined $743K — up 3,915% from $18.5K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new GCTK positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.24M. The largest seller was Boston Financial Management, cutting an estimated $8.97K.

  • 2 institutional investors held GlucoTrack (GCTK) as of Q2 2023, up from 0 in Q1 2023.
  • Funds reported $743K of GlucoTrack stock for Q2 2023, up 3,915% quarter-over-quarter.
  • 2 funds opened new GlucoTrack positions in Q2 2023 and 0 closed out, a net change of +2 holders.
  • The largest GlucoTrack buyer in Q2 2023 was Sabby Management, an estimated $1.24M added.
  • The largest GlucoTrack seller in Q2 2023 was Boston Financial Management, an estimated $8.97K sold.

Based on aggregated 13F filings for Q2 2023.